Arzu Ekici

Arzu Ekici

Auto-generated profile, based on publicly available information

Arzu Ekici

University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Department of Pediatrics, Bursa, Turkey

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
ACAhmet Burak Civan
Ahmet Burak Civan
AEArzu Ekici
Arzu Ekici
CHCengiz Havalı
Cengiz Havalı
NKNevin Kiliç
Nevin Kiliç
MBMuharrem Bostancı
Muharrem Bostancı
Background Although febrile seizure (FS) is generally considered benign and self-limiting, there are differences regarding the risk factors, the prognosis, and the development of epilepsy. Objective To examine the clinical and sociodemographic characteristics of patients diagnosed with FS, and to determine the risks of recurrence and the development of epilepsy. Methods Between 2015 and 2019, we performed a retrospective evaluation of 300 patients with FS followed for at least 24 months. Results The first episode of FS was simple in 72.7% of the patients and complex in 27.3%, and it recurred in 40%. Age under 12 months in the first FS, complex FS, and neurodevelopmental delay were found to statistically increase the risk of recurrence (p < 0.05). A total of 7% of the patients developed epilepsy, and this rate was found to be higher in patients with neurodevelopmental delay and long-term use of antiepileptic drugs (p < 0.001). The development of epilepsy was also observed in 77.8% of the patients with abnormal electroencephalogram (EEG). Epilepsy developed more frequently in those with abnormal EEG (p<0.001). Conclusions Neurodevelopmental delay was an important risk factor for FS recurrence and the development of epilepsy. Abnormality in the EEG is an important risk factor for the development of epilepsy. We found that the long-term prophylactic treatment did not cause decreases in the recurrence of FS nor in the development of epilepsy.

11 March 2021 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
PKPelin Teke Kısa
Pelin Teke Kısa
GYGonca Kılıç Yıldırım
Gonca Kılıç Yıldırım
BHBurcu Ozturk Hismi
Burcu Ozturk Hismi
SYSevil Yıldız
Sevil Yıldız
ÖKÖzge Küsbeci
Özge Küsbeci
NANur Arslan
Nur Arslan

1 November 2012 in Brain and Development
Verified
Journal Article
Closed access
AEArzu Ekici
Arzu Ekici
AYAyten Yakut
Ayten Yakut
NKNurdan Kural
Nurdan Kural
ÖBÖzcan Bör
Özcan Bör
SYSevgi Yimenicioğlu
Sevgi Yimenicioğlu
KCKursat Bora Carman
Kursat Bora Carman

20 March 2025 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
SBSema Bozkaya-Yilmaz
Sema Bozkaya-Yilmaz
NDNihal Olgac Dundar
Nihal Olgac Dundar
NANargiz Aliyeva
Nargiz Aliyeva
AEAtilla Ersen
Atilla Ersen
PGPINAR GENCPINAR
PINAR GENCPINAR
BKBulent Kara
Bulent Kara
The purpose of this study was to enhance understanding of CACNA1A gene variants by elucidating the clinical profiles of patients with different variants. The overlapping features and varying phenotypic characteristics of these neurological disorders pose challenges for clinicians. A data collection form was utilized to gather clinical features, examination details, and treatment information associated with CACNA1A variants. Thirty-one patients were included in the study from 11 different clinics in Turkey. Cases were assessed by comparing their information with existing literature. The study initially included 32 patients from 29 families, with 31 patients meeting the inclusion criteria. Clinical manifestations ranged from congenital onset hypotonia to motor seizures. Within the group of patients, 87% were diagnosed with epilepsy, 61% had neurodevelopmental defects, 32% experienced ataxia, 22% had eye movement problems, 16% suffered from migraines, and 13% had recurrent encephalopathy. Thirty percent of individuals exhibited cerebellar atrophy. A subset of individuals exhibited various forms of cognitive impairment and different kinds of ataxia. Conclusion: CACNA1A variants can lead to structural and functional abnormalities in the Cav2.1 channels, resulting in paroxysmal and/or chronic clinical presentations. The overlapping phenotypes and variable features among family members suggest the influence of environmental factors and modifier genes. A thorough understanding of the range of phenotypic variants and the difficulties encountered by medical professionals is essential for precise diagnosis and efficient treatment approaches in various neurological conditions. Additional research is necessary to clarify the underlying mechanisms that contribute to the various presentations of these variants. What is known: • Variants in the CACNA1A gene disrupt calcium signaling, thereby impacting fundamental developmental processes such as neuronal differentiation, migration, and synapse formation. • Variants in the CACNA1A can lead to neurodevelopmental disorders characterized by intellectual disability, learning difficulties, memory challenges, and problems in social interaction. What is new: • Instances of intrafamilial variability in CACNA1A variants have been identified, with differing clinical manifestations exhibited by affected family members. • Incomplete penetrance is a phenomenon that may occur, as neurodevelopmental or neuropsychiatric findings are not exhibited by some patients with CACNA1A variants.

20 November 2021 in Fetal and Pediatric Pathology
Verified
Journal Article
Closed access
OGorhan gorukmez
orhan gorukmez
OGOzlem Gorukmez
Ozlem Gorukmez
AEArzu Ekici
Arzu Ekici
Introduction: Genetic causes of the intellectual disability Nonsyndromic Autosomal-Recessive Intellectual Disability Syndrome (MRT47, MIM 616193) are mutations in the recently described FMN2 (formin 2 gene). Case report: A boy with intellectual disability had a novel homozygous nonsense mutation (c.2245C > T/p.Gln749*) leading to a premature stop codon in exon 6 of the FMN2 (NM_001305424) gene detected by Clinical Exome Sequencing (CES). Conclusion: Clinical features of a patient with a novel nonsense FMN2 mutation is presented. We urge the change in the OMIM nomenclature from Mental Retardation, Autosomal Recessive 47 (MRT47, MIM 616193) to 'Nonsyndromic Autosomal-Recessive Intellectual Disability Syndrome'.

11 September 2012 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
SYSevgi Yimenicioğlu
Sevgi Yimenicioğlu
AYAyten Yakut
Ayten Yakut
KKKadri Karaer
Kadri Karaer
MZMartin Zenker
Martin Zenker
AEArzu Ekici
Arzu Ekici
KCKursat Bora Carman
Kursat Bora Carman